Market open
MediciNova/$MNOV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MediciNova
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Ticker
$MNOV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
13
Website
MediciNova Metrics
BasicAdvanced
$77M
Market cap
-
P/E ratio
-$0.17
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$77M
Beta
0.72
52-week high
$2.16
52-week low
$1.12
Average daily volume
16K
Financial strength
Current ratio
18.243
Quick ratio
17.775
Long term debt to equity
0.527
Total debt to equity
0.858
Management effectiveness
Return on assets (TTM)
-9.51%
Return on equity (TTM)
-13.32%
Valuation
Price to revenue (TTM)
77.006
Price to book
1.34
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
-9.003
Growth
Earnings per share change (TTM)
-35.49%
3-year revenue growth (CAGR)
-37.00%
3-year earnings per share growth (CAGR)
-11.49%
What the Analysts think about MediciNova
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MediciNova stock.
MediciNova Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MediciNova Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MediciNova News
AllArticlesVideos
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
GlobeNewsWire·2 weeks ago
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
GlobeNewsWire·1 month ago
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MediciNova stock?
MediciNova (MNOV) has a market cap of $77M as of November 08, 2024.
What is the P/E ratio for MediciNova stock?
The price to earnings (P/E) ratio for MediciNova (MNOV) stock is 0 as of November 08, 2024.
Does MediciNova stock pay dividends?
No, MediciNova (MNOV) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next MediciNova dividend payment date?
MediciNova (MNOV) stock does not pay dividends to its shareholders.
What is the beta indicator for MediciNova?
MediciNova (MNOV) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.